Breaking: Promising Sonelokimab's HS Trial Data Propels MoonLake Immunotherapeutics
- June 26th, 2023
- 397 views
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced positive results from its Phase 2 MIRA trial, evaluating the effectiveness and safety of the Nanobody sonelokimab, administered subcutaneously, in patients with moderate-to-severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa is a painful skin condition characterized by lumps that form in areas where skin touches skin.
The trial successfully met its primary endpoint, with a higher proportion of patients treated with sonelokimab achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12.
The results showed that sonelokimab exhibits strong clinical activity compared to other therapies evaluated in similar trials.
At present, $MLTX is trading at $47.59, representing a significant increase of $21.71 (+83.89%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login